3000171945

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE !

06 AUG -7 PM :

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name			
Biotechnology Industry Organization) 		
2. Address Check if different than previously reported			
1225 I St NW Ste 400			
Washington [С	20005-5958	8 USA
3. Principal place of business (if different than line 2)			, , , , , , , , , , , , , , , , , , ,
-	ip or Country		
4a. Contact Name b. Telephone number	c. E-mail		5. Senate ID#
- , , ,	nge@bio.org	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	6245-12
7. Client Name Self Biotechnology Industry Organization			6. House ID# 32505000
	ry 1-June30)	OR Year	End (July 1-December 31
9. Check if this filing amends a previously filed version of this report			
10. Check if this is a Termination Report Termination Date			11. No Lobbying Activit
INCOME OR EXPENSES - Complete Either Line	2 OR Line 13		
12. Lobbying Firms		13. Organi	zations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relat were:	ing to lobbying ac	tivities for this reporting p
Less than \$10,000	Less than \$10,000		
\$10,000 or more	\$10,000 or more	⊠ ⇔ \$	2,600,000
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all			cck box to indicate expens s for description of option
payments to the registrant by any other entity for lobbying	Method A.	• •	ts using LDA definitions only
activities on behalf of the client).	Method B.	Reporting amount Internal Revenue	ts under section 6033(b)(8) of Code
	Method C.	Reporting amoun Revenue Code	ts under section 162(e) of the
			Edit Form > File with
	· · · · · · · · · · · · · · · · · · ·	Senate Password	File with:
Signature Remull	Date	8/2/2006	

LD-2DS (Rev. 4.07)

✓ Page 1

Ö

LD-2DS (Rev. 4.07)

Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations
	· · · · · · · · · · · · · · · · · · ·

LD-2DS (Rev. 4.07)

٦

Ì

Registrant Nan	neBiotechnology Industry Organization	Client Name Biotechnology Industry Organization
engaged in lo	· · · · · · · · · · · · · · · · · · ·	des as necessary to reflect the general issue areas in which the renge the reporting period. Using a separate page for each code, ge(s) as needed.
15. General i	ssue area code AGR - Agriculture	(one per page)
16. Specific I	obbying issues	·
2006 Ei H.R. 54 Cellulos	Ethanol Funding nergy Bill 27: Energy and Water Appropriatio sic Biomass Ethanol Tax Credit ctions 40, 48, 179	n
17. House(s)	of Congress and Federal agencies	contacted None House Senate Other
	griculture; Dept. of Energy; EPA; FDA; each individual who acted as a lol	
	Name	Covered Official Position (if applicable)
Matt	Carr	
Brent	Erikson	,
Grant	Erdel	Administrative Assistant, Rep. Emerson
Eli	Joseph	
Sharon	Bomer (Lauritsen)	Deputy Assist. USTR, Agriculture
Brent	Del Monte	Counsel, House Energy and Commerce Cmte.
Paul	Poteet	Senior Policy Advisor, Rep. Wally Herger
Barbara	Glenn	
James	Eichhorst	·
19. Interest o	of each foreign entity in the specifi	ic issues listed on line 16 above 🔀 Check if None

Registrant Name	Biotechnology Industry Organization	Client Name _	Biotechnology Industry Organization
ADDENDUM	I for General Lobbying Issue Area _	AGR	
16. Specific lo	obbying issues (continued from previou	s page)	
Adventitiou Draft Guid	s Presence dance on Adventitious Presence		

APHIS Part 340 on Adventitious Presence

Cartagena Protocol on Biosafety Implementation of Biosafety Protocol

Foreign Agricultural Biotechnology Laws and Regulations European Biotechnology Laws and Regulations India Regulations on Biotechnology Russia Accession to the World Trade Organization U.S.-Korea Free Trade Agreement U.S.-Malaysia Free Trade Agreement Vietnam Accession to the World Trade Organization Saudi Arabian Biotechnology Laws and Regulations

WTO Dispute on EU Biotechnology Approval Moratorium

Genetically Modified Organism Labeling Russia Accession to the World Trade Organization

Funding for Biomass and Biorefinery Research and Development, Commercialization H.R. 5427: Energy and Water Appropriation

H.R. 6: Energy Policy Act of 2005

H.R. 2744 / H.R. 5384: Agriculture and Related Agencies Appropriation Funding for FDA Funding for USDA Funding for Renewable Energy Programs Funding for Biotechnology Regulatory Services

Ö

LD-2DS

E _ Registrant Name	Biotechnology Industry Or	ganization	Biotechnology Industry Organization Client Name
ADDENDUM for General Lobbying Issue Area AGR			
18. Name of eac	h individual who acte	d as a lobbyist in	this issue area (continued from previous page)
First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Amy	Ehlers		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
			· · · · · · · · · · · · · · · · · · ·

		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	***************************************	

***************************************		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	,,		
.,,,,			
	-		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
455441554455555555555555555555555555555			
(5,7544554445545545545545			
		4	
	,,		

Ö	Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations	
A PARTY	LD-2DS (Rev. 4.07)		·
			Page

Biotechnology Industry Organization

(one per page)

Client Name

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code,

Registrant Name Biotechnology Industry Organization

Deficit Reduction Act Technical Amendments

15. General issue area code

16. Specific lobbying issues

Funding for FDA Funding for USDA

information as requested. Attach additional page(s) as needed.

H.R. 2744: Agriculture and Related Agencies Appropriation

BUD - Budget/Appropriations

9	Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations	
(3)	LD-2DS (Rev. 4.07)		
			Page 8

DDENDUM for General Lobbying Issue Area BUD			
. Specific lo	obbying issues (continued from p	previous page)	
	Supplemental Appropriations or Pandemic Preparedness		
Funding Funding Funding	Agriculture and Related Agencies for the Center for Veterinary Medic for Critical Path at FDA for Renewable Energy Programs for Biotechnology Regulatory Servi	ine	
Funding Funding	Energy and Water Appropriation or Cellulosic Ethanol or Department of Energy Office of or Biomass and Biorefinery Resea		mmercialization
Funding ¹	Labor/HHS/Education Appropriation of NIH for Pandemic Preparedness	on	
			i
			i

LD-2DS

Page <u>9</u>

Biotechnology Industry Organization

(one per page)

Client Name

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code,

Registrant Name Biotechnology Industry Organization

16. Specific lobbying issues

information as requested. Attach additional page(s) as needed.

H.R. 1227, S. 306: Genetic Information Nondiscrimination Act

15. General issue area code ____ CIV - Civil Rights/Civil Liberties

Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations

LD-2DS (Rev. 4.07)

Ö

19. Interest of each foreign entity in the specific issues listed on line 16 above $\boxed{\times}$ Check if None

Ö

LD-2DS (Rev. 4.07)

ť,	Ĺ)
Ļ.	ŗ	١
ť,		
ŗ	•	ŧ
r		
P.	¥	1
P.	¥	1
	*	1

Biotechnology Industry Organization Registrant Name	Biotechnology Industry Organization Client Name
ADDENDUM for General Lobbying Issue Area CPT	<u>r </u>
16. Specific lobbying issues (continued from previous pa	ge)
Changes to Practice for Patent Claims Examinations Safe Harbor exceptions Claims relating to biotechnology	
Patent Reform First-to-file Prior art Post-grant opposition	
H.R. 5418: Bill to establish pilot program in courts pertaini	ng to patents
	,
	ı
	ı
	1
	•
	·
·	•
	•
	:

(C)

LD-2DS

Page <u>12</u>

Registrant Nan	ne Biotechnology Industry Organiza	Client Name Biotechnology Industry Organization
engaged in lo		codes as necessary to reflect the general issue areas in which the relating the reporting period. Using a separate page for each code, page(s) as needed.
15. General i	Ssue area code CSP - Consumo	er Issues/Safety/Protection (one per page)
	obbying issues	
Pharmace	eutical Anti-Counterfeiting	
	ly Modified Organism Labeling Accession to World Trade Organ	nization
Drug Safe	ety	
17. House(s)	of Congress and Federal agenc	ies contacted None House Senate Other
Dept. of A	griculture; Dept. of Commerce; EPA	A; FDA; HHS
18. Name of	each individual who acted as a	lobbyist in this issue area
	Name	Covered Official Position (if applicable)
Grant	Erdel	Admin. Assistant to Rep. Emerson
Amit	Sachdev	
Sara	Radcliffe	
Andrew	Emmett	
Dave	Boyer	Sp Ast to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Brent	Del Monte	Counsel, House Energy and Commerce Cmte.
Paul	Poteet	Senior Policy Advisor, Rep. Wally Herger
Libby	Solon	
Michael	Phillips	
19. Interest o	f each foreign entity in the spe	cific issues listed on line 16 above X Check if None

Ö	Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations		
1200	LD-2DS (Rev. 4.07)			
			Page 13	

00
LΛ
(3)
red
j.

(2)
(\mathfrak{D})
Œ

Biotechnology Industry Organization Registrant Name Client Name	Biotechnology Industry Organization
ADDENDUM for General Lobbying Issue Area CSP	
16. Specific lobbying issues (continued from previous page)	
Drug Importation H.R. 4939: Supplemental Appropriations H.R. 5384: Agriculture and Related Agencies Appropriations H.R. 5441: FY 2007 Homeland Security Appropriations	
Adventitious Presence Draft Guidance on Adventitious Presence Early Food Safety Evaluation APHIS Part 340 on Adventitious Presence	
	1
	t e
	1
	ı
·	
	•
	'

LD-2DS

Biotechnology Industry Organization

Client Name

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
James	Eichhorst	Junix	
	2101110100		
	······································		
***************************************		······································	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	***************************************	
			1
,		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
			1
>+++++++++++++++++++++++++++++++++++++			

·····			
}*************************************			

	······································		
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
*	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			

Biotechnology Industry Organization

Registrant Name

(I)

LD-2DS (Rev. 4.07)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code,

Client Name Biotechnology Industry Organization

(one per page)

Registrant Name Biotechnology Industry Organization

15. General issue area code

information as requested. Attach additional page(s) as needed.

ENG - Energy/Nuclear

Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations

LD-2DS (Rev. 4.07)

ä

ť	١	Į
ţ	1)
ť	J)
*		ĺ
ţ	٠,	
Ŧ	•	١
¢)
¢		
ĺ	7)

Biotechnology Industry Organization Biotechnology Industry Registrant Name Client Name	
ADDENDUM for General Lobbying Issue Area ENG	
16. Specific lobbying issues (continued from previous page)	
Cellulosic Ethanol Tax Credits / Incentives IRC Sections 40, 48, 179 S. 2446: American Fuels Act	
Funding for Biomass and Biorefinery Research and Development, Commercialization H.R. 6: Energy Policy Act of 2005 H.R. 5427: Energy and Water Appropriation	
Funding for the Department of Energy Office of Science H.R. 5427: Energy and Water Appropriation	
Funding for Renewable Energy Programs H.R. 5384: Agriculture and Related Agencies Appropriation	·
	, , ,
	1
	•

Ö

LD-2DS

Page <u>18</u>

Ö

LD-2DS (Rev. 4.07)

' Page 19

T,	
U	
ø	
ķ.	1
ļ	٠
ķiņ	
(

ADDENDUM for General Lobbying Issue Area FOO 16. Specific lobbying issues (continued from previous page) Genetically Modified Organism Labeling Russia Accession to the World Trade Organization	Biotechnology Industry Organization Registrant Name	Biotechnology Industry Organization Client Name
Genetically Modified Organism Labeling Russia Accession to the World Trade Organization		
Genetically Modified Organism Labeling Russia Accession to the World Trade Organization		
Russia Accession to the World Trade Organization	16. Specific lobbying issues (continued from previous p	page)
	Genetically Modified Organism Labeling	
	Russia Accession to the world Trade Organization	
		•
		· I
		l .
		•
		•
		i I
		•

ල ල

LD-2DS

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**,

Biotechnology Industry Organization

(one per page)

Registrant Name Biotechnology Industry Organization

15. General issue area code

16. Specific lobbying issues

Cellulosic Ethanol Funding 2006 Energy Bill

information as requested. Attach additional page(s) as needed.

H.R. 5427: Energy and Water Appropriation

FUE - Fuel/Gas/Oil

Ö	Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations	
``	LD-2DS (Rev. 4.07)		n 21
			Page 21

ĺ	ļ)	
	()	
)		
		-	
•	•	1	
	•)	
ļ	7) 1	
t	1		

Biotechnology Industry Organization Registrant Name	Client Name	Biotechnology Industry Organization	
ADDENDUM for General Lobbying Issue Area			
16. Specific lobbying issues (continued from previous	ıs page)		
Tax Incentives for Cellulosic Ethanol IRC Sections 40, 48, 179 S. 2446: American Fuels Act H.R. 5348: Agriculture and Related Agencies Appro H.R. 6: Energy Policy Act of 2005	ppriation		
Funding for Biomass and Biorefinery Research and E H.R. 6: Energy Policy Act of 2005 H.R. 5427: Energy and Water Appropriation	Development, Cor	nmercialization	
		,	
		•	
		Y	
		(
		·	
		·	

Ö

LD-2DS

Page _22__

Registrant Name Biotechnology Industry Organization		Client Name Biotechnology Industry Organization	
engaged in I		s necessary to reflect the general issue areas in which the reporting period. Using a separate page for each code as needed.	
15. General	issue area code HCR - Health Issues	(one per page)	
16. Specific	lobbying issues		
Pharmac	ceutical Anti-Counterfeiting		
Critical F	ath		
Drug Sat	fety		
		1	
17. House(s)) of Congress and Federal agencies cont	acted None House Senate Other	
Dept. of 0	Commerce; FDA; HHS; White House Office		
18. Name of	each individual who acted as a lobbyis	t in this issue area	
	Name	Covered Official Position (if applicable)	
Grant	Erdel	Administrative Assistant, Rep. Emerson	
Amit	Sachdev	4	
Sara	Radcliffe	1	
Andrew	Emmett	1	
Eli	Joseph		
Dave	Boyer	Sp Asst to Sec, HHS, HHS Leg Aff Sp Ast Oversight	
Chris	Colwell		
Tom	DiLenge	Chief Counsel, House Homeland Security Cmte.	
Brent	Del Monte	Counsel, House Energy and Commerce Cmte.	
19. Interest of	of each foreign entity in the specific issu	ues listed on line 16 above Check if None	

Ö	Printed Name and Title Brent Del Monte, Vice President for Federal Government Relations LD-2DS (Rev. 4.07)	,
	ED-2D3 (Rev. 4.07)	Page23

Ø	
٥	
'n	
1	
No.	
<u>.</u>	
\Box	
C	

Biote	echnology Industry Organization	Client Name	Biotechnology Industry Organization
DDENDUM for	General Lobbying Issue Are	ea HCR	
5. Specific lobbying	ng issues (continued from prev	vious page)	
FDA Performano	e		· · · · · · · · · · · · · · · · · · ·
Follow-On Biolog	gics		¥.
Information Te FDA Review P Drug Advertisir	ractices		, ,
Finances Drug Safety Critical Path			
H.R. 5533, S Vaccine Tracki	f Countermeasures . 1973 (prev. S. 2564) Biodefens ng		cine and Drug Development Act
Countermeasu H.R. 4939: S Funding for Pre H.R. 5533, S Antitrust, Procu	Supplemental Appropriations eparedness . 1973 (prev. S. 2564) Biodefens	e and Pandemic Vac nent, Bioterrorism Re	authorization, Orphan Drug, BARDA
	riculture and Related Agencies A oplemental Appropriation	ppropriation	
Ryan White Case Covered Drugs	e Act Reauthorization List/ADAP		
Non-Interference H.R. 4939: Sup	pplemental Appropriation		
Tricare Retail Ph H.R. 5122, S. 2	armacy 2767: Department of Defense Au	thorization	
Medicaid Progra S. 1932: Defici	m/Rebates/340B t Reduction Act		
S. 3175 Life-Sav	ing Medicines Export Act		
 	6: Canatia Information Non discr		•

) 1 LD-2DS

Page <u>24</u>

Biotechnology Industry Organization

8. Name of eac	th individual who acte	d as a lobbyist in	this issue area (continued from previous page)
First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
usie	Ahn		Senior Legislative Assistant, Rep. Mike Honda
ibby	Solon		
***************************************	······································		

		······	
()))			
	······································		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
			**
			······································
			;
		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
***************************************			······

Biotechnology Industry Organization

Registrant Nan	ne Biotechnology Industry Organization	Client Name Biotechnolo	gy Industry Organization
engaged in lo	GACTIVITY. Select as many codes as obbying on behalf of the client during the as requested. Attach additional page(s) a	reporting period. Using a sep	
15. General i	ssue area code HOM - Homeland Securit	y (one pe	er page)
16. Specific I	obbying issues		
H.R. 56 H.R. 49	for Pandemic Preparedness 647: Labor/HHS/Education Appropriation 939: Supplemental Appropriation 533, S. 1873 (prev. S. 2564): Biodefense a	ind Pandemic Vaccine and Dru	ig Development Act
17. House(s)	of Congress and Federal agencies conta	eted None House	Senate Other
HHS			
18. Name of	each individual who acted as a lobbyist	n this issue area	•
	Name	Covered Official Pos	ition (if applicable)
Grant	Erdel	Administrative Assistant, R	ep. Emerson
Amit	Sachdev	,	
Eli	Joseph		
Dave	Boyer	Sp Asst to Sec HHS; HHS	Leg Aff Sp Ast, Översight
Chris	Colwell		1
Tom	DiLenge	Chief Counsel, House Hom	eland Security Cmte.
Brent	Del Monte	Counsel, House Energy an	d Commerce Cmte.
Susie	Ahn	Senior Legislative Assistan	t, Rep. Mike Honda
Libby	Solon		1
19. Interest o	f each foreign entity in the specific issue	s listed on line 16 above 🔀	Check if None

Printe

Registrant Name	Biotechnology Industry Organization	Client Name	Biotechnology Industry Organization
ADDENDUM	1 for General Lobbying Issue Area	НОМ	
16. Specific lo	obbying issues (continued from previous	ous page)	
	e Countermeasures Liability 39: Supplemental Appropriation		
	e Vaccine Tracking Pandemic & All-Hazards Preparedness	Act	
Biodefense	R&D Tax Credit		
	e Information Technology to Improve Situ Pandemic & All-Hazards Preparedness		3
	S. 1873 (previously S. 2564): Biodefens	e and Pandemic V	accine Drug Development Act
Antitrus Valley c Procure Animal	f Death		
BARDA Bioterro	rism Reauthorization		
Orphan Identific	ation of Countermeasures		1
			1

LD-2DS

Page <u>27</u>

Registrant Nam	e Biotechnology Industry Organiza	tion Client Name Bio	otechnology Industry Organization
engaged in lol		uring the reporting period. Usi	e general issue areas in which the re ng a separate page for each code,
15. General is	sue area code LAW - Law Enfo	prcement/Crime/Criminal Justice	(one per page)
16. Specific lo	obbying issues		,
H.R. 4239	, S. 1926: Animal Enterprise Te	rrorism Act	
17. House(s)	of Congress and Federal agenc	ies contacted None X	House Senate Other
18. Name of 6	each individual who acted as a	1	
Danak	Name		fficial Position (if applicable) nergy and Commerce Cmte.
Brent Barbara	Del Monte Glenn	Couriser, Flouse L	nergy and commerce office.
James	Eichhorst		
			<u>;</u>
			· · · · · · · · · · · · · · · · · · ·
19. Interest o	feach foreign entity in the spe-	cific issues listed on line 16 ab	ove 🔀 Check if None

Printed Name and Title Brent Del Monte, Vice President for Federal Government Relations

LD-2DS (Rev. 4.07)

Page __28__

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re

Client Name Biotechnology Industry Organization

Registrant Name Biotechnology Industry Organization

Ö	Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations	·
	LD-2DS (Rev. 4.07)		Page <u>29</u>

Registrant Na	me Biotechnology Industry Organiz	ation Client Name Biotechnology Industry Organization
engaged in l		codes as necessary to reflect the general issue areas in which the r during the reporting period. Using a separate page for each code I page(s) as needed.
15. General	issue area code	/Disease Research/Clinical Labs (one per page)
16. Specific	lobbying issues	
H.R. 49 H.R. 50	for Pandemic Preparedness 939: Supplemental Appropriatior 647: Labor/HHS/Education Appr 533, S. 1873 (prev. S. 2564): Bio	
17. House(s) of Congress and Federal agen	cies contacted None House Senate Other
FDA; HH	S Feach individual who acted as a	lobbyist in this issue area
	Name	Covered Official Position (if applicable)
Grant	Erdel	Administrative Assistant, Rep. Emerson
Amit	Sachdev	,
Sara	Radcliffe	
Alan	Eisenberg	Policy Advisor, Rep. James Greenwood
Eli	Joseph	1
Dave	Boyer	Sp. Ast. to Sec, HHS; HHS Leg Aff Sp Ast, Oversight
Chris	Colwell	
Tom	DiLenge	Chief Counsel, House Homeland Security Cmte.
Brent	Del Monte	Counsel, House Energy and Commerce Cmte.
19. Interest	of each foreign entity in the spe	ecific issues listed on line 16 above Kheck if None

Ö	Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations	
	LD-2DS (Rev. 4.07)		
			, Page <u>30</u>

Re	Biotechnology Industry Organization Biotechnology Industry gistrant Name Client Name	Organization
ΑI	DDENDUM for General Lobbying Issue Area MED	i
16	. Specific lobbying issues (continued from previous page)	
	Orphan Drug H.R. 5080: Orphan Drug Tax Credit	ı
	Funding for Critical Path at FDA H.R. 5384: Agriculture and Related Agencies Appropriation	•
•	Funding for the National Institute of Health H.R. 5647: Labor/HHS/Education Appropriation	i
	Stem Cell Research H.R. 182, S. 876: Human Cloning Ban & Stem Cell Research Protection Act H.R. 2520: Stem Cell Therapeutic & Research Act H.R. 596, S. 681: Cord Blood Stem Cell Act H.R. 810: Stem Cell Research S. 2754: Alternative Pluirpotent Stem Cell Therapies Enhancement Act S. 2504: Fetus Farming Prohibition Act	
	Biodefense R&D Tax Credit	•
	H.R. 5533, S. 1873 (previously S. 2564): Biodefense and Pandemic Vaccine and Drug Deve	lopment Act
	Valley of Death Animal Model Development BARDA Orphan Drug	1
	H.R. 5578: Human Subject Protection Act	1
		•
		1
		k (
		1
		1
		•

b LD-2DS

Page <u>31</u>

Registrant Name	Biotechnology Industry O	rganization	Biotechnology Industry Organization Client Name			
ADDENDUM	for General Lobby	ing Issue Area	MED			
18. Name of each	8. Name of each individual who acted as a lobbyist in this issue area (continued from previous page)					
First Name	Name Last Name	Suffix	Covered Official Position (if applicable)			
Susie	Ahn	· · · · · · · · · · · · · · · · · · ·	Senior Legislative Assistant, Rep. Mike Honda			
Paul	Poteet		Senior Policy Advisor, Rep. Wally Herger			
Libby	Solon		,			
)H()10100H()///////////////////////////////////						
HIGH COLOR OF THE			,			
)			ı			
			ı			
			· ·			

			i			
			'			
History			,			
111111111111111111111111111111111111111						
,,						

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code,

Client Name Biotechnology Industry Organization

Registrant Name Biotechnology Industry Organization

information as requested. Attach additional page(s) as needed.

Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations
	· · · · · · · · · · · · · · · · · · ·

LD-2DS (Rev. 4.07)

Ö

Ø
1
(J)
hond
1
red
\odot
(3)
(3)
(2)

Biotechnology Industry Organization gistrant Name Client Nam	Biotechnology Industry Organization ae
DDENDUM for General Lobbying Issue Area MMM	ı
. Specific lobbying issues (continued from previous page)	
	•
DRA, Proposed Rules on Competitive Bidding and Inpatient Rule	
Medicare Part B Drug Reimbursement	
	,
,	
	;
	1
	l
	1
	•
	•
	Y
·	r

Ö

LD-2DS

Page <u>34</u>

Biotechnology Industry Organization

Client Name

Registrant Name Biotechnology Industry Organization

Ğ		Brent Del Monte, Vice President for Federal Government Relations		
	LD-2DS (Rev. 4.07)		Page35	

Biotechnology Industry Organization

Client Name

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code,

Registrant Name Biotechnology Industry Organization

information as requested. Attach additional page(s) as needed.

LD-2DS (Rev. 4.07)

Ö

Ö

LD-2DS

Page _37_

N
00
CD

-
tind
(2)
\odot
(3)
(3)

Registrant Name	Biotechnology Industry Organiza	ation	Biotechnology Industry Organization Client Name	
ADDENDUM	for General Lobbying Is	ssue Area SCI	<u></u>	
			issue area (continued from previous page)	
First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
Susie	Ahn	Sullix	Senior Legislative Assistant, Rep. Mike Honda	3
Paul	Poteet		Senior Policy Advisor, Rep. Wally Herger	
Libby	Solon		,	
Amy	Ehlers			
				,,,,,,,,
мыноними			1	
		······		*****
.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
				.,
***************************************		,	1	
		,		. ,
NATURAL DESIGNATION OF THE PROPERTY OF THE PRO				
		,		
, , , , , , , , , , , , , , , , , , , ,		•	·	
			1	
1887D-18811/2881			,	. * * * * * * * * * * * * * * * * * * *
			Add a page to continue additing lobbyists	for th

Page <u>38</u>

Biotechnology Industry Organization

Client Name

Registrant Name Biotechnology Industry Organization

Ö	Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations	1
" 	LD-2DS (Rev. 4.07)		
	•		Page 39
			1

Registrant Name _ Biotechnology Industry Organization

	obbying on behalf of the client as requested. Attach additiona	during the reporting period. Using a separate page for each code page(s) as needed.
15. General i	ssue area code	/Internal Revenue Code (one per page)
16. Specific I	obbying issues	ı
H.R. 1 H.R. 2	x Credit on Conference Report 736, S. 627: Investment in Ame 830: Pension Protection Act of 297: Reconciliation	
17. House(s)	of Congress and Federal agen	cies contacted None House Senate Other
	of Treasury each individual who acted as a	lobbyist in this issue area
	Name	Covered Official Position (if applicable)
Matt	Carr	
Brent	Erikson	
Lauren	Choi	
Tom	DiLenge	Chief Counsel, House Homeland Security Cmte.
Brent	Del Monte	Counsel, House Energy and Commerce Cmte.
Morrie	Ruffin	
Paul	Poteet	Senior Policy Advisor, Rep. Wally Heger
19. Interest o	of each foreign entity in the spo	ecific issues listed on line 16 above \(\sum \) Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re

Client Name Biotechnology Industry Organization

LD-2DS (Rev. 4.07)

ľU
00
(D)
177
15
सम
\mathbb{C}
(Ç)
(\mathfrak{I})
(3)

Biotechnology Industry Organization Registrant Name Client 1	Biotechnology Industry Organization Name
ADDENDUM for General Lobbying Issue Area TAX	:
16. Specific lobbying issues (continued from previous page)	,
Biodefense R&D Tax Credit H.R. 4297: Reconciliation	
Tax Incentives for Cellulosic Ethanol IRS Code Sections 40, 48, 179 S. 2446: American Fuels Act	·
Taxes on Net Operating Losses H.R. 4082, S. 1893: Biotechnology Future Investment Expansion H.R. 5115: Compete Act	on Act
H.R. 5080: Orphan Drug Tax Credit	
	'
	i ·
	1
	,
	•
	•
•	

LD-2DS

Ō

Ö

Registrant Nam	ne Biotechnology Industry Organization	Client Name Biotechnology Industry Organization
engaged in lo		des as necessary to reflect the general issue areas in which the ng the reporting period. Using a separate page for each code ge(s) as needed.
15. General is	TRD - Trade (Dom	estic & Foreign) (one per page)
16. Specific le	obbying issues	
H.R. 53	ortation 39: Supplemental Appropriation 84: Agriculture and Related Agenci 41: FY 2007 Homeland Security Ap	
17. House(s)	of Congress and Federal agencies	contacted None House Senate Other
	griculture; NSC; USPTO; Dept. of State	
	Name	Covered Official Position (if applicable)
Lila	Feisee	
Grant	Erdel	Administrative Assistant, Rep. Emerson
Sharon	Bomer (Lauritsen)	Deputy Assistant USTR, Agriculture
Dave	Boyer	Sp. Ast. to Sec, HHS, HHS Leg Aff Sp Ast, Oversight
Brent	Del Monte	Counsel, House Energy and Commerce Cmte.
Paul	Poteet	Senior Policy Advisor, Rep. Wally Herger
Libby	Solon	
James	Eichhorst	,
Amit	Sachdev	
19. Interest o	f each foreign entity in the specifi	c issues listed on line 16 above \(\sum \) Check if None

Ō	Printed Name and Title	Brent Del Monte, Vice President for Federal Government Relations	<u>i</u>
	LD-2DS (Rev. 4.07)		i

Ø
0
ን
Party.
"
כ
)

Biotechnology Industry Organization	Biotechnology Industry Organization
ADDENDUM for General Lobbying Issue Area TRD	•
16. Specific lobbying issues (continued from previous page)	
Foreign Agricultural Biotechnology Laws and Regulations India Regulations on Biotechnology Russia Accession to the World Trade Organization U.S. Malaysia Free Trade Agreement Negotiations Vietnam Accession to the World Trade Organization U.S. Korea Free trade Agreement Negotiations Saudi Arabian Agricultural Biotechnology Laws	
Cartagena Protocol on Biosafety Implementation of Biosafety Protocol	ı
Doha Trade Round Issue Related to Genetic Origin Disclosure CBD/TRIPS Genetic Origin Disclosure Requirements	
European Biotechnology Laws and Regulations WTO Dispute on EU Biotechnology Approval Moratorium	· ·
Genetically Modified Organism Labeling Russian Accession to the World Trade Organization	
Sec. 332 ITC Study	, , , , , , , , , , , , , , , , , , ,
WTO Case on Traceability and Labelling	ı
S. 3175: Life-Saving Medicines Export Act	l
	ı
	•

Registrant Nam	ne Biotechnology Industry Organization	Client Name Biotechnology Industry Organization
engaged in lo		s necessary to reflect the general issue areas in which the ree reporting period. Using a separate page for each code, as needed.
15. General is	ssue area code PHA - Pharmacy	(one per page)
16. Specific le	obbying issues	
H.R. 5	ortation 939: Supplemental Appropriations 384: Agriculture and Related Agencies A 441: FY 2007 Homeland Security Appro	
17. House(s)	of Congress and Federal agencies cont	acted None House Senate Other
	t. of Commerce; FDA; HHS; White House Of	
	Name	Covered Official Position (if applicable)
Grant	Erdel	Administrative Assistant, Rep. Emerson
Andrew	Emmett	•
Jayson	Slotnik	
Eli	Joseph	
Dave	Boyer	Sp Ast to Sec HHS; HHS Leg Aff Sp Ast, Oversight
Chris	Colwell	
Tom	DiLenge	Chief Counsel, House Homeland Security Cmte.
Brent	Del Monte	Counsel, House Energy and Commerce Cmte.
Libby	Solon	
19. Interest o	f each foreign entity in the specific issu	ues listed on line 16 above 🔀 Check if None

LD-2DS (Rev. 4.07)

Ō

(C)
(3)
red Is
red
(2)
(3)
0

Biotechnology Industry Organization Registrant Name Clier	Biotechnology Industry Organization nt Name
ADDENDUM for General Lobbying Issue Area PHA	
16. Specific lobbying issues (continued from previous page)	•
Pharmaceutical Anti-Counterfeiting	
Biodefense Vaccine Tracking S.3678: Pandemic & All-Hazards Preparedness Act	
DRA, Proposed rules on Competitive Bidding and Inpatient Ru	ıle
Medicare Part B Drug Reimbursement	·
Ryan White Care Act Reauthorization Covered Drugs List/ADAP	i.
Tricare Retail Pharmacy H.R. 5122, S. 2767: Department of Defense Authorization	
Medicaid Program/Rebates/340B S.1932: Deficit Reduction Act	÷
S. 3175: Life-Saving Medicines Export Act	
	' '
	•
·	1
	•
	·

(**5**

LD-2DS

Page <u>46</u>

ę		
ţ		
¢		
Ţ	*	١
ţ		
P		
ĺ	7)
(•	
Ć		1
ř		١

Registrant Name _	Biotechnology Industry Or	ganization	Biotechnology Industry Organization Client Name			
ADDENDUM	for General Lobbyi	ng Issue Area	PHA			
18. Name of eac	18. Name of each individual who acted as a lobbyist in this issue area (continued from previous page)					
Plant Name	Name	מ ניי	Covered Official Position (if applicable)			
First Name Amit	Last Name Sachdev	Suffix				
	······	4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
			' '			
			1			
	·		1			
			· ·			
			·			
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
			:			
			1			
·····		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
	1011(47(1)11)1(1)1(1)1(1)1(1)1(1)1(1)1(1)1(1)1	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
		,				
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			1			
***************************************	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
			1			

		,,,,,	·			
			Add a page to continue additing lobbyists for this			

Registrant Name Biotechnology Industry Organization

Printed Name and Title Brent Del Monte, Vice President for Federal Government Relations